Table 4.

Rejection and graft-versus-host disease: analysis of pretransplantation factors

FactorRejectors (n = 9)Nonrejectors (n = 35)P value (rejection)Grades II-IV GVHD (n = 17)Grades 0-I GVHD (n = 19)P value (GVHD)
Male patient7/9 (78%)24/35 (67%).7011/17 (65%)13/19 (68%).81
Male donor4/9 (44%)21/35 (58%).479/17 (53%)12/19 (63%).54
Intensive prior therapy4-150 1/9 (11%)31/35 (86%)< .000115/17 (88%)16/19 (84%)1.0
Donor age in years48 (40-72)57 (33-73).8053 (33-73)58 (38-65).78
Patient age in years54 (40-71)56 (31-72).7656 (31-70)57 (36-72).87
CD34+ cell dose × 106/kg9.1 (3.8-15.1)6.9 (3.1-17.5).516.4 (3.3-16.1)6.9 (3.1-17.5).57
CD3+ cell dose × 108/kg3.3 (1.0-4.5)3.4 (0.7-8.3).583.6 (0.7-7.2)3.1 (0.8-8.3).86
Diagnosis of CML4/9 (44%)4/35 (11%).042/17 (12%)3/19 (16%)1.0
  • For abbreviations, see Tables 1 and 2.

  • Data are presented as n (%) or median (range). Rejection analysis includes 44 patients who received low-dose TBI/CSP/MMF and excludes patient FH14726, who also received fludarabine.

  • F4-150 Intensive prior therapy includes prior autograft, prior intensive chemotherapy for acute leukemia, or more than 3 cycles of a fludarabine-containing regimen.